R&D News | pharmaphorum

Sunday 25 October 2026

News

News

Novartis snaps up food allergy firm Excellergy for $2bn

Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.

News

Wave's stock wavers on obesity drug data

Wave's stock wavers on obesity drug data

Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don't seem to agree.

News

Novo unveils first data for 'triple G' agonist in diabetes

Novo unveils first data for 'triple G' agonist in diabetes

Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.

News

AI in drug discovery & development: News watch, March 2026

AI in drug discovery & development: News watch, March 2026

Recent developments in the biopharma AI world include a big financing for Verily, and updates from Zealand, Latent Labs, Insilico, and BMS/insitro.

News

Update: Rumour confirmed as MSD buys Terns for $6.7bn

Update: Rumour confirmed as MSD buys Terns for $6.7bn

MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7bn bid to acquire Terns Pharma.

News

Karyopharm eyes Xpovio filing in myelofibrosis on mixed data

Karyopharm eyes Xpovio filing in myelofibrosis on mixed data

Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.